What Denver Patients Are Actually Paying for GLP-1 Drugs in 2026
Compounded semaglutide is legally disappearing, telehealth ads are everywhere, and brand-name Wegovy runs $1,349 a month. Here's what Denver patients are actually paying across every access route r…
Compounded semaglutide is legally disappearing, telehealth ads are everywhere, and brand-name Wegovy runs $1,349 a month. Here’s what Denver patients are actually paying across every access route right now — and what open enrollment means for your out-of-pocket costs.
The math changed fast. Eighteen months ago, a Denver resident could pay around $250 a month for compounded semaglutide through an independent prescriber, fill it at a local 503A pharmacy, and have what felt like a sustainable treatment plan. Today, that same patient is staring at brand-name Wegovy at roughly $1,349 a month — or stopping a medication that was working.
That’s not an abstract regulatory story. For the tens of thousands of Colorado residents who accessed GLP-1 therapy through the compounding route during the 2023–2025 shortage period, it’s a financial emergency. And it’s happening at exactly the moment when national telehealth platforms are flooding every search result with ads for programs that may not be able to deliver what they’re advertising.
No local publication has put Denver-specific prices in one place. This guide does that. It covers what local clinics charge, what compounding pharmacies can legally dispense in 2026, what each major Colorado insurance plan actually requires for prior authorization, and what the honest annual cost looks like across every access route. It also covers what uninsured Denver patients can realistically access — because that story gets almost no coverage, and it should.
The Three Ways to Get a GLP-1 Prescription in Denver
The upfront and ongoing non-drug costs vary significantly across access routes and routinely get left out of the price comparisons circulating online. Worth mapping before you get to drug costs.
Route 1: A Denver-area weight loss clinic or endocrinologist. Denver Weight Loss Clinic in Cherry Creek offers both cash-pay and insurance options with GLP-1 management programs; confirm current consultation and monthly management fees directly with the clinic before using any number for budgeting. Milestone Weight Loss and Aesthetics in Greenwood Village runs a more concierge-oriented cash-pay model. Both typically require an initial consultation, baseline labs (metabolic panel, HbA1c, thyroid at minimum), and ongoing monthly or quarterly management visits.
For patients who want rigorous medical oversight — and some genuinely do — the Colorado Center for Obesity Management at the University of Colorado Anschutz Medical Campus in Aurora is the academic referral destination. Patients with comorbidities like Type 2 diabetes, hypertension, or sleep apnea benefit most from this level of care. It’s also running three-to-six month wait times for new patients in 2026. That wait doesn’t appear on any price sheet, but for anyone with time-sensitive treatment needs, it’s a real cost. Plan around it.
Route 2: Compounding pharmacy via independent prescriber. This route defined the 2023–2025 GLP-1 access explosion and is now legally constrained in ways most patients haven’t been fully informed of. A Denver prescriber writing a compounded semaglutide script in 2026 for a patient without documented allergy or sensitivity to brand-name inactive ingredients is writing outside current federal legal parameters. Some prescribers are still doing it. The regulatory details matter and are explained below.
Route 3: National telehealth platform. Hims, Ro, Noom Med, and what’s left of Calibrate. If you’ve Googled anything weight-related in the past year, you know the ads. The pricing that got these platforms attention — often $199 to $299 a month — reflected compounded semaglutide availability, which is now legally curtailed. What these platforms can actually prescribe and fill in 2026 has narrowed considerably. What patients will actually pay for a brand-name alternative through a telehealth channel is not clearly communicated in most platform marketing. We’ll come back to that gap.
Brand-Name Drug Costs, Savings Cards, and What the Coupon Math Actually Means
Wegovy (semaglutide for weight management, Novo Nordisk) carries a list price of approximately $1,349 per month as of early 2026. Ozempic (semaglutide for Type 2 diabetes, same manufacturer) runs roughly $950 per month at list price. Mounjaro and Zepbound (tirzepatide, Eli Lilly) carry their own list prices — confirm current figures directly with your pharmacy, as Lilly pricing has shifted alongside manufacturer savings program changes.
Novo Nordisk offers a savings card for Wegovy. For commercially insured patients who qualify, it can bring monthly out-of-pocket cost to as low as $0. The catch: that requires your insurance to cover Wegovy, which many plans don’t. For patients without insurance, Novo Nordisk’s WeightLoss Care program has offered Wegovy at $499 per month with income thresholds. Verify current program availability and income caps directly with Novo Nordisk before you count on that number — terms have shifted before.
The savings card cannot be used with Medicare, Medicaid, TRICARE, or any other federal health insurance program. This eliminates a substantial Denver population: veterans at Buckley Space Force Base on TRICARE, patients who’ve transitioned to Medicare, low-income residents on Health First Colorado. Eli Lilly’s comparable program for Zepbound carries the same federal exclusion.
One more thing worth flagging: even a $0 copay card doesn’t eliminate the cost absorbed by your insurer, and some plans now explicitly exclude coupon-assisted fills from counting toward your deductible. If you’re counting on Wegovy spending to move you toward your out-of-pocket maximum, confirm with your plan whether those fills count. Don’t assume.
Compounding Pharmacies in Denver: What Is and Is Not Legal in 2026
The regulatory situation has been widely misreported, and Denver patients are making financial decisions based on outdated information.
The FDA removed semaglutide from its drug shortage list in October 2024. That triggered a compliance timeline giving 503A pharmacies — traditional compounders filling patient-specific prescriptions — until approximately March to April 2025 to stop compounding semaglutide for general use. 503B outsourcing facilities, which produce drugs at larger scale for healthcare facilities, had a somewhat extended timeline but by mid-2025 were operating under significant restrictions.
Belmar Pharmacy in Lakewood is one of Colorado’s most prominent 503A compounding pharmacies and was dispensing semaglutide during the shortage period. As a 503A facility, Belmar is now prohibited from compounding semaglutide for general weight management or diabetes use under the post-shortage framework. One narrow legal carve-out exists: a prescriber can request a compound if there’s documented clinical evidence of patient allergy or sensitivity to a specific inactive ingredient in the brand-name product. Not a preference for the compounded form. Not a cost objection. A specific inactive ingredient, with genuine clinical documentation. Contact Belmar directly to confirm current dispensing status.
Leiters in Englewood operates as a 503B outsourcing facility, subject to FDA registration and Current Good Manufacturing Practice standards. In 2026, Leiters’ ability to compound semaglutide is constrained by the post-shortage enforcement posture. Both facilities’ options are subject to change as FDA guidance evolves — last month’s information isn’t reliable enough. Contact them directly.
The Colorado State Board of Pharmacy follows federal enforcement posture on this issue. Call them directly for questions about specific pharmacies’ current authorization status.
Bottom line for patients: if you’re receiving compounded semaglutide from a 503A source in 2026 without documented allergy-based justification, your prescription is operating outside current federal legal parameters. Enforcement action isn’t necessarily imminent. But the legal grounding isn’t solid, and the supply could be cut off abruptly if FDA enforcement intensifies. That’s a real planning risk, and it’s worth treating it as one now.
Colorado Insurance Coverage, Plan by Plan
This is where most Denver patients’ real out-of-pocket cost gets determined. The details matter most during open enrollment, when plan selection locks in your formulary access for the year. For a closer look at how alternative coverage structures are affecting what Denver residents pay for routine care, our health & wellness coverage has tracked these shifts across multiple specialties.
Kaiser Permanente Colorado has historically required completion of an internal behavioral weight management program before approving a GLP-1 for weight management. Coverage for Ozempic in patients with documented Type 2 diabetes follows standard diabetic medication protocols and is generally accessible. For weight management, expect a prior authorization process requiring BMI documentation (30 or above, or 27 with a qualifying comorbidity) and evidence of Kaiser program participation. Confirm your specific plan’s current formulary tier for Wegovy with Kaiser member services — not a broker, not based on what a friend’s plan covers.
Cigna/Evernorth covers GLP-1s for weight management on many Colorado employer plans, though not all. Prior authorization criteria typically require BMI documentation, at least one weight-related comorbidity, and documented prior non-pharmacological treatment. Here’s the critical caveat: Cigna administers many self-insured employer plans in Denver, and self-insured employers set their own formulary. A Cigna insurance card does not guarantee GLP-1 coverage. Your employer’s specific plan document does.
Anthem BCBS Colorado imposes similar prior authorization requirements. Anthem also administers a significant number of self-insured Denver employer plans, and GLP-1 exclusions are common in those plans. Some Anthem individual and small-group marketplace plans include GLP-1 coverage with prior authorization; others place them on a non-covered tier. Before selecting a plan at open enrollment, search that plan’s formulary tool for Wegovy and Zepbound. Confirm the specific drug tier.
Health First Colorado (Medicaid) presents the most stringent requirements. Ozempic is covered under the preferred drug list for members with a Type 2 diabetes diagnosis — the most straightforward coverage on this list. Wegovy for weight management requires prior authorization with BMI documentation and, critically, documented participation in a behavioral intervention program for a minimum of six months before approval. The prior authorization process runs through Colorado’s Department of Health Care Policy and Financing (HCPF). Current criteria and the preferred drug list are at hcpf.colorado.gov. And because it’s worth stating plainly: the federal insurance exclusion eliminates the manufacturer savings card entirely for Medicaid members.
A significant portion of large Denver employers are self-insured — they bear the direct cost of employee drug claims and write their own formularies. This is why two employees at different companies, both carrying a “Cigna” or “Anthem” card, can have completely different GLP-1 coverage. No insurance card tells you this upfront. The documents that do are your Summary of Benefits and Coverage and your pharmacy benefit formulary. Your HR department is required to make both available.
If you’re selecting a plan during open enrollment, search the specific formulary for “semaglutide” and “tirzepatide” — not just “GLP-1.” Confirm whether weight management or only diabetes indications are covered. This is the step most people skip and then regret.
What Three Major Denver Employers Actually Cover
Employer-specific benefit details are among the most searched and hardest-to-find information during open enrollment season.
City of Denver offers employee health benefits through a self-insured structure administered through multiple carriers. GLP-1 coverage status varies by plan tier. City employees can review 2026 formulary and benefit documents through the city’s employee benefits portal. If you’re comparing plans during open enrollment, ask HR specifically whether Wegovy and Zepbound are covered for weight management — not just diabetes. Get the prior authorization criteria in writing before you select a plan.
Xcel Energy, one of the Denver metro’s largest private employers, sits squarely in the middle of a national HR debate over GLP-1 coverage. Some large utilities added coverage in 2025 to stay competitive in hiring; others added cost-sharing requirements or pulled back. Xcel employees should review their 2026 benefits guide specifically for specialty drug tier classification of GLP-1s and any step-therapy requirements. Confirm current terms with Xcel HR directly.
UCHealth is both the major academic health system and one of the metro’s largest employers. As the system operating the Colorado Center for Obesity Management at Anschutz, UCHealth has more direct institutional experience with GLP-1 therapy than most employers — which presumably shapes its benefits design. Employees can access plan documents through the UCHealth Benefits Portal. There’s also a practical advantage worth noting: internal referrals to the Anschutz obesity program may move faster than outside referrals, potentially cutting into that three-to-six month external wait.
If you learn during benefits research that your employer has added or dropped GLP-1 coverage for the 2026 plan year, document it before your enrollment window closes.
Total Annual Cost: What the Drug Alone Actually Costs Across Routes
Brand-name Wegovy at list price — no insurance, no savings program — runs $1,349 per month, about $16,188 per year. This is the number every other option should be measured against.
Wegovy through Novo Nordisk’s uninsured savings program costs around $5,988 per year at the $499 monthly tier. Income thresholds and program availability for 2026 must be confirmed directly with Novo Nordisk. Don’t build a treatment plan around this figure without verifying it first.
The telehealth route is where the advertised price and the realistic price diverge most sharply — and most visibly. Hims and Ro built their GLP-1 programs around compounded semaglutide at $199 to $299 a month. With compounded semaglutide no longer legally available for general use, these platforms are moving toward brand-name products or tirzepatide alternatives. As of early 2026, the sub-$300 figure still appearing in some advertising doesn’t reflect what a new patient will actually pay. Platforms that have shifted to brand-name drugs are pricing accordingly — $1,000-plus monthly, with a subscription fee on top.
Local prescribers offer advantages that cost tables miss. A Denver-based physician can order and review in-person metabolic labs, manage comorbid conditions within the same clinical relationship, and maintain continuity if your treatment plan changes. Calibrate, once a prominent GLP-1 telehealth platform with real Colorado presence, experienced significant financial difficulty. Patients who’d built year-long treatment plans around that platform had to restart elsewhere. The risk of tying a chronic disease management plan to a startup’s continued existence is real — and worth weighing against the convenience pitch.
For Denver residents weighing how a direct primary care relationship might reduce the non-drug overhead of GLP-1 management, how direct primary care works in Denver and whether it saves money is worth reading alongside this cost breakdown.
Denver Health and the Patients Who Cannot Access Any of the Above
The cost analysis above is largely irrelevant for the significant portion of Denver’s population that’s uninsured, underinsured, or on Medicaid and excluded from manufacturer savings programs. That’s worth saying directly.
Denver Health, the safety-net system serving uninsured and underinsured residents through its main campus and community health centers across the city, is the realistic access point for this population. Denver Health’s formulary includes GLP-1s for their FDA-approved diabetes indication. Ozempic is prescribable for patients with Type 2 diabetes under standard diabetic care protocols. For weight management in a patient without a diabetes diagnosis, the picture is harder. Uninsured patients at Denver Health who don’t qualify for Health First Colorado face brand-name GLP-1 costs that savings cards can’t help with — the federal exclusion eliminates that option entirely. Patients just above Medicaid eligibility but well below middle income often fall through this gap, and there’s no clean solution for that population right now.
The Cherry Creek and LoHi concierge weight loss clinic model has no practical relevance for lower-income Denver patients. Worth stating plainly, because those clinics dominate search results and create a misleading picture of what’s actually available.
The most meaningful option for uninsured Denver residents is Health First Colorado eligibility screening. Colorado has expanded Medicaid, and income thresholds are broader than many residents realize — a single adult earning up to roughly 138 percent of the federal poverty level qualifies. Colorado’s PEAK portal at colorado.gov/peak handles enrollment. A patient on Health First Colorado with a Type 2 diabetes diagnosis has a realistic path to Ozempic coverage. A patient seeking Wegovy for weight management without diabetes faces the six-month behavioral intervention documentation requirement, but there is a path.
Colorado’s 2024 and 2025 legislative sessions included discussion of expanded GLP-1 coverage through state employee plans and Medicaid. The Department of Health Care Policy and Financing has gradually moved to expand weight management coverage. Patients tracking this should monitor HCPF’s Pharmacy Clinical Policy Bulletins at hcpf.colorado.gov.
What Denver Patients on Compounded Semaglutide Should Do Right Now
If you started GLP-1 therapy on compounded semaglutide during the 2023–2025 period and haven’t had a conversation with your prescriber about the regulatory shift, that conversation is overdue.
Ask your prescriber directly whether your compound is being filled under a documented allergy exception. If the answer isn’t yes, your supply is legally uncertain. That’s not a reason to panic — it’s a reason to plan now, not when you run out.
Get into a prior authorization process with your insurer before your current supply runs out. The PA process for Wegovy or Zepbound takes time. A denial triggering an appeal extends that further. Starting when you have a month of compounded supply left is not early enough.
If you don’t have insurance that covers GLP-1s, use that time to confirm your eligibility for manufacturer savings programs.
Talk with your prescriber about tirzepatide as an alternative. Zepbound and Mounjaro are distinct molecules from semaglutide, and the compounding restrictions on semaglutide don’t automatically extend to tirzepatide. That said, FDA enforcement on compounded tirzepatide has also tightened — this isn’t a clean workaround. Check the current FDA drug shortage list for tirzepatide at FDA.gov, since shortage status directly affects compounding permissibility. Your prescriber can assess whether tirzepatide is clinically appropriate and whether your insurer’s formulary covers it differently.
If you’re comparing insurance plans during open enrollment, make GLP-1 formulary status a primary filter. The difference between a plan that covers Wegovy at a specialty drug tier and one that excludes it entirely is roughly $16,000 per year in out-of-pocket drug cost at list price. That’s not a rounding error in plan comparison — it’s the whole calculation. Search each plan’s formulary for “semaglutide” and “tirzepatide” before you finalize your selection. Denver-area residents purchasing through Connect for Health Colorado can compare formularies through the plan comparison tool before the open enrollment deadline.
If you’re uninsured, start with PEAK. Colorado Medicaid eligibility is broader than most residents assume, and enrollment changes your access significantly — particularly for Ozempic if you have a diabetes diagnosis.
The honest version of the GLP-1 market in Denver in 2026 is this: the patients who were best positioned to use these drugs before the compounding route opened up — commercially insured, working for employers who kept GLP-1 coverage, with bandwidth to fight through prior authorization — are still fine. Everyone who found access through compounding or telehealth during the shortage period is now facing an access cliff that nobody in the ad ecosystem is being honest about. The clinical evidence for these medications is strong. The supply routes that made them broadly accessible are not. Those two things are in real tension, and no amount of $299-a-month advertising changes it.
The numbers above are real. The access routes are real. The regulatory constraints are real. Anyone making a coverage decision this open enrollment season deserves to know what’s actually available — not what’s being advertised.
Rates and formulary details are current as of publication. Drug list prices, insurance prior authorization criteria, and manufacturer savings program terms change frequently; confirm directly with your pharmacy, insurer, and prescriber before making treatment or coverage decisions.
